Cell Therapeutics sells Zevalin stake to Spectrum
This article was originally published in Scrip
Executive Summary
Cell Therapeutics (CTI) is to sell its stake in the Zevalin (ibritumomab tiuxetan) joint venture that it set up with Spectrum Pharmaceuticals at the end of last year.